MCID: MNN013
MIFTS: 65

Meningitis

Categories: Ear diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningitis

MalaCards integrated aliases for Meningitis:

Name: Meningitis 12 74 53 54 42 3 44 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9471
ICD9CM 34 322.9
MeSH 44 D008581
NCIt 50 C26828
SNOMED-CT 67 154983000
ICD10 32 G03 G03.8 G03.9
UMLS 71 C0025289

Summaries for Meningitis

NINDS : 53 Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get encephalitis or meningitis. Causes of encephalitis and meningitis include viruses, bacteria, fungus, and parasites. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately. Symptoms of encephalitis that might require emergency treatment include loss of consciousness, seizures, muscle weakness, or sudden severe dementia. Other symptoms include: sudden fever, headache, vomiting, heightened sensitivity to light, stiff neck and back, confusion and impaired judgment, drowsiness, weak muscles, a clumsy and unsteady gait, irritability. In more severe cases, people may have problems with speech or hearing, vision problems, and hallucinations. Symptoms of meningitis, which may appear suddenly, often include: high fever, severe and persistent headache, stiff neck, nausea, sensitivity to bright light, vomiting, and changes in behavior such as confusion, sleepiness, and difficulty waking up. In infants, symptoms of meningitis or encephalitis may include fever, vomiting, lethargy, body stiffness, unexplained irritability, and a full or bulging fontanel (the soft spot on the top of the head).

MalaCards based summary : Meningitis is related to viral meningitis and tuberculous meningitis, and has symptoms including seizures, tremor and fever. An important gene associated with Meningitis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Methotrexate and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and pituitary, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A central nervous system disease that is characterized by an inflammation of the pia-arachnoid meninges. It can be caused by growth of bacteria, fungi, or parasites within the subarachnoid space or by the growth of bacteria or viruses within the meningeal or ependymal cells.

MedlinePlus : 42 Meningitis is inflammation of the thin tissue that surrounds the brain and spinal cord, called the meninges. There are several types of meningitis. The most common is viral meningitis. You get it when a virus enters the body through the nose or mouth and travels to the brain. Bacterial meningitis is rare, but can be deadly. It usually starts with bacteria that cause a cold-like infection. It can cause stroke, hearing loss, and brain damage. It can also harm other organs. Pneumococcal infections and meningococcal infections are the most common causes of bacterial meningitis. Anyone can get meningitis, but it is more common in people with weak immune systems. Meningitis can get serious very quickly. You should get medical care right away if you have A sudden high fever A severe headache A stiff neck Nausea or vomiting Early treatment can help prevent serious problems, including death. Tests to diagnose meningitis include blood tests, imaging tests, and a spinal tap to test cerebrospinal fluid. Antibiotics can treat bacterial meningitis. Antiviral medicines may help some types of viral meningitis. Other medicines can help treat symptoms. There are vaccines to prevent some of the bacterial infections that cause meningitis. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Meningitis is an inflammation (swelling) of the protective membranes covering the brain and spinal cord. A bacterial or viral infection of the fluid surrounding the brain and spinal cord usually causes the swelling. However, injuries, cancer, certain drugs, and other types of infections also can cause meningitis. It is important to know the specific cause of meningitis because the treatment differs depending on the cause.

Wikipedia : 74 Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord,... more...

Related Diseases for Meningitis

Diseases in the Meningitis family:

Viral Meningitis Chronic Meningitis
Bacterial Meningitis

Diseases related to Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1808)
# Related Disease Score Top Affiliating Genes
1 viral meningitis 33.3 IL6 IFNG CXCL8 CRP ADA
2 tuberculous meningitis 33.3 TNF TLR2 LYZ CXCL8 ADA
3 meningococcal meningitis 33.2 TLR2 MBL2 CFP
4 aseptic meningitis 33.2 TNF IL1B IL10 IFNG CXCL8 CFI
5 haemophilus meningitis 33.2 TNF IL1B CRP
6 cryptococcal meningitis 33.1 MBL2 IFNG ADA
7 fungal meningitis 33.0 TNF IL6 IL10 IFNG CXCL8 ALB
8 listeria meningitis 32.8 TNF ADA
9 chronic meningitis 32.8 IL1B CRP ALB
10 bacterial meningitis 32.6 TNF TLR2 MBL2 LACTB IL6 IL1B
11 lymphocytic choriomeningitis 32.5 TLR2 IL6 CXCL8
12 encephalitis 32.5 TNF TLR2 IL6 IL1B IL10 CCL4
13 haemophilus influenzae 32.5 TNF TLR2 LACTB CXCL8
14 meningoencephalitis 32.4 TNF IL6 IL10 CRP ALB
15 listeriosis 32.3 TNF TLR2 MBL2 IL6 IL1B IL10
16 meningococcemia 32.3 MBL2 IL1B CFP
17 cysticercosis 32.1 IL6 IL1B IL10
18 neurosyphilis 32.1 TLR2 IL10 CXCL8
19 leptospirosis 32.0 TNF TLR2 IL6 IL1B IL10 IFNG
20 mannose-binding lectin deficiency 32.0 MBL2 IL6 CFP
21 neisseria meningitidis infection 32.0 TLR2 MBL2 LACTB CFP CD46
22 cerebral palsy 31.9 TNF MBL2 IL6 IL1B IL10 CXCL8
23 tuberculous peritonitis 31.9 IFNG CRP ALB ADA
24 extrapulmonary tuberculosis 31.9 TLR2 MBL2 IL1B IL10 IFNG CRP
25 spinal cord disease 31.8 TNF IL6 IL1B IL10 CRP ALB
26 cryptococcosis 31.8 TNF MBL2 IL10 IFNG
27 vasculitis 31.7 TNF MBL2 IL6 CRP
28 arachnoiditis 31.7 TNF IL1B CRP
29 behcet syndrome 31.7 TNF TLR2 MBL2 IL6 IL1B IL10
30 pleural empyema 31.5 IL6 CRP ALB ADA
31 miliary tuberculosis 31.5 TNF IFNG CRP ALB ADA
32 chickenpox 31.5 TNF IL6 IL10 IFNG CRP ALB
33 myelitis 31.5 TNF IL6 IL10 CXCL8
34 exanthem 31.5 TNF IL6 IL1B IL10 IFNG CXCL8
35 herpes zoster 31.5 TNF TLR2 IL10 IFNG
36 poliomyelitis 31.4 TNF IL10 IFNG
37 mumps 31.4 TNF IL6 IL1B IL10 IFNG CXCL8
38 toxic shock syndrome 31.4 TNF TLR2 IL6 IL1B IL10 IFNG
39 brain edema 31.4 IL6 IL1B IFNG CRP ALB
40 acquired immunodeficiency syndrome 31.3 TNF IL6 IL1B IL10 IFNG CRP
41 cerebritis 31.3 TNF IL1B CRP
42 otitis media 31.3 TNF TLR2 MBL2 LACTB IL6 IL1B
43 rubella 31.3 TNF IL6 IL1B IL10 IFNG
44 epidural abscess 31.3 CRP ALB
45 viral encephalitis 31.2 TNF IL6 IL1B IL10 CXCL8
46 epidemic typhus 31.2 TNF IL10 CRP
47 disseminated intravascular coagulation 31.2 TNF IL6 IL10 CRP
48 purpura 31.2 TNF IL6 IL1B IL10 IFNG CRP
49 mycobacterium tuberculosis 1 31.2 TNF TLR2 MBL2 IL10 IFNG CCL4
50 osteomyelitis 31.2 TNF TLR2 IL6 IL1B IL10 IFNG

Comorbidity relations with Meningitis via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Meningitis
Deficiency Anemia Hypertension, Essential

Graphical network of the top 20 diseases related to Meningitis:



Diseases related to Meningitis

Symptoms & Phenotypes for Meningitis

UMLS symptoms related to Meningitis:


seizures, tremor, fever, back pain, headache, pruritus, syncope, hemiplegia, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, meningism, hyperexplexia

MGI Mouse Phenotypes related to Meningitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ADA ALB CD55 CFI CFP CRP
2 cardiovascular system MP:0005385 10.29 ADA ALB CD46 CFP CRP IFNG
3 immune system MP:0005387 10.24 ADA ALB CD55 CFI CFP CRP
4 hematopoietic system MP:0005397 10.21 ADA CD55 CFI IFNG IL10 IL1B
5 digestive/alimentary MP:0005381 10.06 ADA ALB IFNG IL10 IL6 LYZ
6 liver/biliary system MP:0005370 9.92 ADA ALB IFNG IL10 IL6 LYZ
7 muscle MP:0005369 9.91 ADA ALB CD55 IFNG IL10 IL6
8 neoplasm MP:0002006 9.76 ALB IFNG IL10 IL1B IL6 LYZ
9 renal/urinary system MP:0005367 9.61 ADA ALB CD55 CFI IFNG IL6
10 skeleton MP:0005390 9.32 ADA CFP IFNG IL10 IL1B IL6

Drugs & Therapeutics for Meningitis

Drugs for Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 301)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
2
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Lactitol Approved, Investigational Phase 4 585-86-4 157355
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Zidovudine Approved Phase 4 30516-87-1 35370
9
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
10
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
11
Nevirapine Approved Phase 4 129618-40-2 4463
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
13
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
14 Folic Acid Antagonists Phase 4
15 Vitamin B Complex Phase 4
16 Antimetabolites Phase 4
17 Vitamin B9 Phase 4
18 Dermatologic Agents Phase 4
19 Folate Phase 4
20 BB 1101 Phase 4
21 HIV Protease Inhibitors Phase 4
22
protease inhibitors Phase 4
23 Gastrointestinal Agents Phase 4
24 Anti-Retroviral Agents Phase 4
25 Gentamicins Phase 4
26 Cathartics Phase 4
27 Laxatives Phase 4
28 Anti-HIV Agents Phase 4
29 Reverse Transcriptase Inhibitors Phase 4
30 Lactams Phase 4
31 beta-Lactams Phase 4
32 penicillins Phase 4
33 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
34 Complement Factor H Phase 4
35 Vaccines Phase 4
36 Neuromuscular Blocking Agents Phase 4
37
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
38
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3 21645-51-2
39
Vancomycin Approved Phase 3 1404-90-6 441141 14969
40
Glycerol Approved, Investigational Phase 3 56-81-5 753
41
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
42
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
43
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
44
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
45
Meropenem Approved, Investigational Phase 3 96036-03-2, 119478-56-7 64778 441130
46
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
47
Sulfamethoxazole Approved Phase 3 723-46-6 5329
48
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
49
Zinc Approved, Investigational Phase 3 7440-66-6 32051
50
Ampicillin Approved, Vet_approved Phase 2, Phase 3 69-53-4 6249

Interventional clinical trials:

(show top 50) (show all 435)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
2 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
3 Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial Unknown status NCT01478035 Phase 4 Phenytoin;placebo
4 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
5 Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis Unknown status NCT02590510 Phase 4 methotrexate
6 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
7 A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants Completed NCT00581035 Phase 4
8 A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
9 Determination of Gentamicin Dosing in Neonatal Patients for Use in the Uniject Pre-filled Syringe [A Three-site Study at: 1) Dhaka Shishu Hospital, Dhaka Bangladesh; 2) Christain Medical Center, Vellore, India; and 3) Aga Khan University Medical Center, Karachi, Pakistan] Completed NCT00198601 Phase 4 Gentamicin in Uniject Pre-filled syringe
10 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
11 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
12 Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis, Especially of Pneumococcal Meningitis, in Angola. Completed NCT01540838 Phase 4 Infusion with paracetamol;Bolus without paracetamol
13 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
14 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
15 An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi Completed NCT01247909 Phase 4 Ceftriaxone v penicillin and gentamicin
16 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Completed NCT02864927 Phase 4
17 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
18 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
19 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
20 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Completed NCT03723525 Phase 4
21 Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections. Completed NCT01745679 Phase 4 Ceftriaxone treatment
22 The Impact of Vaccination With a Serogroup A Meningococcal Conjugate Vaccine on Carriage of Serogroup A Meningococci in Mali and Niger Completed NCT01119482 Phase 4
23 Evaluation of the Effect of Tetravalent (A, C, Y, W-135) Meningococcal Conjugate Vaccine on Serogroup-Specific Carriage of Neisseria Meningitidis Completed NCT00119080 Phase 4
24 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
25 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
26 A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB) Completed NCT02080559 Phase 4
27 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
28 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
29 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
30 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
31 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
32 A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age Completed NCT00310635 Phase 4
33 Open Label Study of Lung and Serum Immunoglobulin Responses to 7-Valent Pneumococcal Conjugate Vaccine in HIV Infected and Non-HIV Infected Malawian Adults Completed NCT00371878 Phase 4
34 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
35 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
36 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Completed NCT02569632 Phase 4
37 Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China Completed NCT01430611 Phase 4
38 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
39 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
40 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
41 Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135 Completed NCT00850603 Phase 4
42 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study) Recruiting NCT03682939 Phase 4
43 A Sourcing Study to Collect Human Biological (Serum) Samples From Healthy Adults Recruiting NCT03493919 Phase 4
44 A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years Not yet recruiting NCT04450498 Phase 4
45 Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors Not yet recruiting NCT04224311 Phase 4
46 Mild Induced Hypothermia to Treat Severe Community Acquired Meningitis in Adults Admitted to Intensive Care Unit Terminated NCT00774631 Phase 4
47 Amikacin Penetration Into the Cerebrospinal Fluid: Pharmacokinetic/Pharmacodynamic Analysis in Adults With Hospital Acquired Gram-negative Meningitis Associated With Intracranial Pressure Monitoring and Draining Devices Withdrawn NCT00362245 Phase 4 Systemic and Intra-Thecal Amikacin Therapy
48 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin Prophylaxis as a Response to a Meningococcal Meningitis Epidemic Withdrawn NCT03431675 Phase 4 Ciprofloxacin
49 Immunogenicity, Reactogenicity and Safety Assessment of the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos / FIOCRUZ in Infants, Children and Adolescents Unknown status NCT02858570 Phase 2, Phase 3
50 Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine

Search NIH Clinical Center for Meningitis

Cochrane evidence based reviews: meningitis

Genetic Tests for Meningitis

Anatomical Context for Meningitis

MalaCards organs/tissues related to Meningitis:

40
Spinal Cord, Brain, Pituitary, Endothelial, Neutrophil, Breast, Myeloid

Publications for Meningitis

Articles related to Meningitis:

(show top 50) (show all 30038)
# Title Authors PMID Year
1
Viral meningitis: an overview. 61 42
33392820 2021
2
Klebsiella pneumoniae-related invasive liver abscess syndrome complicated by purulent meningitis: a review of the literature and description of three cases. 42 61
33407192 2021
3
The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? 42
33280014 2020
4
Comparative analysis of cerebrospinal fluid adenosine deaminase in tuberculous and non-tuberculous meningitis. 61 54
20399005 2010
5
Adenosine deaminase and tuberculous meningitis--a systematic review with meta-analysis. 54 61
20001225 2010
6
HLA-DRB1*01 allele and low plasma immunoglobulin G1 concentration may predispose to herpes-associated recurrent lymphocytic meningitis. 54 61
19879913 2010
7
Very late-onset group B Streptococcus meningitis, sepsis, and systemic shigellosis due to interleukin-1 receptor-associated kinase-4 deficiency. 54 61
19814626 2009
8
[A case of listeria meningitis showed high levels of adenosine deaminase in cerebrospinal fluid]. 54 61
19928691 2009
9
C-reactive protein as an indicator of aqueductal gliosis and hydrocephaly in neonatal meningitis. 61 54
18581011 2008
10
Bacterial meningitis: rapid diagnosis and microbial profile: a multicentered study. 54 61
19301695 2008
11
Comparative study of cerebrospinal fluid adenosine deaminase activity in patients with meningitis. 54 61
17899959 2007
12
A case of Listeria meningitis associated with increased adenosine deaminase in cerebrospinal fluid. 61 54
17141462 2007
13
A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. 54 61
17266837 2007
14
Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis. 54 61
16920154 2006
15
Serum concentrations of interleukin-1 alpha, interleukin-6 and tumor necrosis factor-alpha in neonatal sepsis and meningitis. 54 61
17013473 2006
16
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults. 54 61
17333738 2006
17
Expression of innate immune complement regulators on brain epithelial cells during human bacterial meningitis. 61 54
16948860 2006
18
Interleukin-1alpha, interleukin-6 and tumor necrosis factor-alpha levels in children with sepsis and meningitis. 54 61
16635168 2006
19
[Lymphocytis meningitis: Listeria monocytogenes is a potential risk in a immunocompetent child]. 61 54
16185855 2005
20
Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. 54 61
15825022 2005
21
Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. 54 61
15105095 2004
22
[Concentration of proinflammatory cytokines (TNF-alpha, IL-8) in the cerebrospinal fluid and the course of bacterial meningitis]. 54 61
15230146 2004
23
Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. 61 54
12952922 2003
24
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. 54 61
12480084 2003
25
Neurotrophin-4 and glial cell line-derived neurotrophic factor in cerebrospinal fluid from meningitis/encephalitis patients. 61 54
12213609 2002
26
Interleukin-8 levels in children with bacterial, tuberculous and aseptic meningitis. 54 61
12003295 2002
27
Worldwide variation in the incidence of Haemophilus influenzae type b meningitis and its association with ampicillin resistance. 61 54
11939404 2002
28
The possible role of cerebrospinal fluid adenosine deaminase activity in the diagnosis of tuberculous meningitis in adults. 54 61
11792470 2002
29
[Does the estimation of acute phase protein concentrations in cerebrospinal fluid and/or in serum in patients with viral meningitis carry diagnostic importance? Part I. Lymphocytic meningitis caused by epidemic parotitis]. 61 54
12666587 2002
30
[Clinical study of 33 children with systemic pneumococcal infections]. 54 61
11806134 2001
31
Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. 61 54
11709004 2001
32
[Chemokines in meningitis of different etiologies]. 54 61
11320578 2001
33
Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. 61 54
11763415 2001
34
Adenosine deaminase levels in cerebrospinal fluid and serum in the diagnosis of tubercular meningitis. 61 54
11191154 2000
35
Follistatin (FS) in human cerebrospinal fluid and regulation of FS expression in a mouse model of meningitis. 54 61
11124865 2000
36
Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. 61 54
10992482 2000
37
Serum C-reactive protein in the differential diagnosis of childhood meningitis. 61 54
11059546 2000
38
[Serial measurement of anti-interleukin-8 IgG autoantibody in cerebrospinal fluid of infants with bacterial meningitis]. 61 54
11109762 2000
39
Fc gamma receptor allotypes in children with bacterial meningitis. A preliminary study. 61 54
10028861 1998
40
[Quantitative levels of serum amyloid A protein and other proteins in cerebrospinal fluid and serum of patients with meningitis]. 61 54
9800479 1998
41
The production of macrophage inflammatory protein-1alpha in the cerebrospinal fluid at the initial stage of meningitis in children. 61 54
9396559 1997
42
Levels of interleukin-6, CRP and alpha 2 macroglobulin in cerebrospinal fluid (CSF) and serum as indicator of blood-CSF barrier damage. 54 61
9350334 1997
43
[Bacterial meningitis and CSF cytokines]. 54 61
15034315 1997
44
[Evaluation of tumor necrosis factor and C-reactive protein level determination in cerebrospinal fluid of meningitis and encephalitis]. 54 61
9424322 1997
45
[Detection of Neisseria meningitidis group B antigens by MB-Dot-Elisa test in patients with meningitis]. 54 61
9162589 1997
46
[Nitric oxide, TNF-alpha and IL-8 in cerebrospinal fluids of tuberculous and cryptococcic meningitis]. 61 54
10072993 1997
47
Detection of N. meningitidis group B antigens by MB-Dot-ELISA in patients with meningitis. 61 54
8897721 1996
48
Chemokines in the cerebrospinal fluid of patients with meningitis. 54 61
8764560 1996
49
Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. 61 54
8801091 1996
50
C-reactive protein in childhood meningitides. 54 61
10829968 1996

Variations for Meningitis

Expression for Meningitis

Search GEO for disease gene expression data for Meningitis.

Pathways for Meningitis

Pathways related to Meningitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 TNF TLR2 MBL2 LYZ IRAK4 IL6
2
Show member pathways
13.51 TNF TLR2 IRAK4 IL6 IL1B IL10
3
Show member pathways
13.46 TNF IRAK4 IL6 IL1B IL10 IFNG
4
Show member pathways
13.35 TNF IL6 IL1B IL10 CXCL8 CXCL1
5
Show member pathways
13.1 TNF TLR2 MBL2 IRAK4 IL6 IL1B
6
Show member pathways
13.03 TNF TLR2 IRAK4 IL6 IL1B CXCL8
7
Show member pathways
12.96 TNF IL6 IL1B IL10 IFNG CXCL8
8 12.92 TNF TLR2 IRAK4 IL6 IL1B IFNG
9
Show member pathways
12.92 TNF TLR2 IRAK4 IL6 IL1B IFNG
10
Show member pathways
12.84 TNF TLR2 IRAK4 IL6 IL1B CXCL8
11
Show member pathways
12.82 TNF TLR2 IRAK4 IL6 IL1B CXCL8
12
Show member pathways
12.76 TNF TLR2 IRAK4 IL6 IL1B
13
Show member pathways
12.72 TNF TLR2 IL6 IL1B IL10 IFNG
14
Show member pathways
12.71 TNF TLR2 IL6 IL1B IL10 IFNG
15
Show member pathways
12.7 TNF IL6 IL1B IL10 IFNG CXCL1
16 12.68 TNF TLR2 IRAK4 IL1B IL10 IFNG
17
Show member pathways
12.46 TNF IL6 IL10 CXCL8 CXCL1 CCL4
18
Show member pathways
12.45 TNF IL6 IL1B IFNG CRP ALB
19
Show member pathways
12.44 TNF IRAK4 IL6 IL1B IFNG CXCL8
20
Show member pathways
12.43 TNF TLR2 IL6 IL1B IFNG CXCL8
21
Show member pathways
12.38 TNF TLR2 IRAK4 IL6 CXCL8
22
Show member pathways
12.38 TNF IL6 IL1B IL10 IFNG CXCL8
23
Show member pathways
12.38 TNF TLR2 IRAK4 IL1B IL10 IFNG
24 12.36 TNF IRAK4 IL6 IL1B CXCL8 CXCL1
25 12.29 TNF IL6 IL1B IL10 CXCL8
26 12.29 TNF TLR2 IRAK4 IL6 IL1B IL10
27
Show member pathways
12.27 TNF IL6 IL1B IL10
28
Show member pathways
12.27 MBL2 CRP CFP CFI CD55 CD46
29 12.25 TNF TLR2 IL6 IFNG
30
Show member pathways
12.24 MBL2 CRP CFI CD55 CD46
31
Show member pathways
12.24 TNF TLR2 IRAK4 IL6 IL1B IFNG
32 12.19 MBL2 CFI CD55 CD46
33 12.18 TNF IRAK4 IL6 IL1B IL10 CXCL8
34 12.12 TNF IL6 IL1B IL10 CXCL8
35 12.11 TNF IL6 IL1B IFNG CXCL8 CXCL1
36 12.09 TNF IL6 IL10 IFNG
37 12.08 IL6 IL1B IFNG CXCL8 CXCL1
38 12.07 TNF IL6 IL1B CXCL1
39 12.03 TNF IRAK4 IL1B CXCL8 CXCL1 CCL4
40 12.02 TNF IL6 IL1B CXCL8
41 12.01 TNF IL6 IL1B CD55
42
Show member pathways
11.97 TLR2 IL6 IL1B IFNG
43 11.91 TNF IL1B IL10 IFNG
44 11.88 TNF IL6 IL1B IL10 IFNG
45 11.83 IL6 IFNG CXCL8
46
Show member pathways
11.83 MBL2 CFP CD55
47 11.83 TNF TLR2 IL6 IL1B IFNG CXCL8
48 11.82 TNF TLR2 IL6 IL10
49
Show member pathways
11.81 TNF TLR2 IL6 IL1B IL10 IFNG
50
Show member pathways
11.8 TNF IFNG CXCL8

GO Terms for Meningitis

Cellular components related to Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF MBL2 LYZ IL6 IL1B IL10
2 cell surface GO:0009986 9.63 TNF TLR2 MBL2 CD55 CD46 ADA
3 extracellular space GO:0005615 9.53 TNF MBL2 LYZ IRAK4 IL6 IL1B
4 specific granule lumen GO:0035580 9.5 LYZ CXCL1 CFP
5 tertiary granule lumen GO:1904724 9.43 LYZ CXCL1 CFP

Biological processes related to Meningitis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.18 TLR2 MBL2 IRAK4 CFP CFI CD55
2 neutrophil degranulation GO:0043312 10.12 TLR2 LYZ CXCL1 CFP CD55
3 negative regulation of cell proliferation GO:0008285 10.09 TLR2 IL6 IL1B IL10 CXCL8 CXCL1
4 innate immune response GO:0045087 10.06 TLR2 MBL2 IRAK4 CRP CFP CFI
5 defense response to bacterium GO:0042742 10.03 TNF MBL2 LYZ IL10 CFP
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF TLR2 IL6 IL1B
7 positive regulation of gene expression GO:0010628 9.97 TNF TLR2 IL6 IL1B IFNG CXCL8
8 complement activation, classical pathway GO:0006958 9.96 MBL2 CRP CFI CD55 CD46
9 regulation of complement activation GO:0030449 9.95 CFP CFI CD55 CD46
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 TNF IL6 IL1B IL10
11 positive regulation of inflammatory response GO:0050729 9.91 TNF TLR2 IL1B IFNG
12 neutrophil chemotaxis GO:0030593 9.9 CXCL8 CXCL1 CCL4
13 chemokine-mediated signaling pathway GO:0070098 9.89 CXCL8 CXCL1 CCL4
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 TNF IL6 IFNG
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR2 IL1B
16 response to glucocorticoid GO:0051384 9.89 TNF IL6 IL10
17 positive regulation of T cell proliferation GO:0042102 9.88 IL6 IL1B CD46
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 TNF IRAK4 IL6
19 regulation of insulin secretion GO:0050796 9.88 TNF IL6 IL1B IFNG
20 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IL6 IL1B IL10 CXCL8 CXCL1
21 humoral immune response GO:0006959 9.87 TNF IL6 IFNG
22 positive regulation of interleukin-1 beta production GO:0032731 9.87 TNF IL6 IFNG
23 positive regulation of cytokine production GO:0001819 9.87 TNF IL10 IFNG
24 positive regulation of phagocytosis GO:0050766 9.85 TNF IL1B IFNG
25 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B IFNG
26 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR2 IL6 IL1B
27 acute-phase response GO:0006953 9.84 MBL2 IL6 CRP
28 positive regulation of interleukin-10 production GO:0032733 9.84 TLR2 IL6 CD46
29 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 IL10
30 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TLR2 IL1B
31 positive regulation of interleukin-6 production GO:0032755 9.83 TNF TLR2 IL6 IL1B IFNG
32 microglial cell activation GO:0001774 9.82 TNF TLR2 IFNG
33 positive regulation of chemokine production GO:0032722 9.8 TNF TLR2 IL6 IFNG
34 negative regulation of neurogenesis GO:0050768 9.79 TNF IL6 IL1B
35 positive regulation of glial cell proliferation GO:0060252 9.77 TNF IL6 IL1B
36 embryonic digestive tract development GO:0048566 9.77 TNF CXCL8 ADA
37 cytokine-mediated signaling pathway GO:0019221 9.76 TNF IRAK4 IL6 IL1B IL10 CXCL8
38 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.75 TNF IL1B IFNG
39 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 TNF IL1B IL10
40 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 IL10 IFNG
42 defense response to Gram-positive bacterium GO:0050830 9.73 TNF TLR2 MBL2 LYZ IL6 CRP
43 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
44 neutrophil mediated immunity GO:0002446 9.72 IRAK4 IL6
45 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
46 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL6 IL1B
47 regulation of complement-dependent cytotoxicity GO:1903659 9.7 IL10 CD55
48 opsonization GO:0008228 9.7 MBL2 CRP
49 response to molecule of bacterial origin GO:0002237 9.7 TLR2 IL10 CXCL8
50 negative regulation of cytokine production involved in immune response GO:0002719 9.69 TNF IL10

Molecular functions related to Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF IL6 IL1B IL10 IFNG CXCL8
2 chemokine activity GO:0008009 9.13 CXCL8 CXCL1 CCL4

Sources for Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....